P B Jayakumar

Stories by P B Jayakumar

Birlas get Kerala nod for Rs 4,000-cr IT park

Birlas get Kerala nod for Rs 4,000-cr IT park

Rediff.com   21 May 2010

The Aditya Birla Group has received in-principle approval from the Kerala government to set up a Rs 4,000-crore (Rs 40 billion) IT and Biotech Knowledge Park and a branch of Birla Institute of Technology and Sciences (BITS) at Kozhikode.

L&T on aggressive expansion abroad

L&T on aggressive expansion abroad

Rediff.com   6 May 2010

Larsen & Toubro, India's largest engineering, construction and technology company, is aggressively expanding its footprint across various places abroad

Pfizer, Wyeth sue Ranbaxy over drug

Pfizer, Wyeth sue Ranbaxy over drug

Rediff.com   3 May 2010

Pfizer, the world's largest drug company, and Wyeth have sued Daiichi Sankyo-owned Ranbaxy Laboratories in a US court for infringing the patent rights of Wyeth's drug, Rapamune.

Elder Pharma to hire 1,000 for rural sales

Elder Pharma to hire 1,000 for rural sales

Rediff.com   15 Apr 2010

Elder Pharma employs about 3,300 people in India, with about 2,700 professionals in marketing and sales. This recruitment will help Elder Pharma to have one of the largest drug sales force in India, like market leaders such as Cipla, Ranbaxy, Piramal Healthcare and Lupin.

US firm drags Lupin to court

US firm drags Lupin to court

Rediff.com   19 Mar 2010

Cephalon, a US-based drug maker, has filed a lawsuit against Lupin Ltd and its US subsidiary Lupin Pharmaceuticals for challenging the patents on its sleep disorder drug Nuvigil.

'Our Indian operations are a great success story'

'Our Indian operations are a great success story'

Rediff.com   10 Mar 2010

Andrew Witty, chief executive of GlaxoSmithKline (GSK), the world's second-largest drug company, was in India this week as part of the dedication of an albandazole manufacturing facility at Nashik to the World Health Organization (WHO)'s global programme to eliminate Lymphatic Filariasis.

Indian pharma in midst of corporate transformation

Indian pharma in midst of corporate transformation

Rediff.com   15 Feb 2010

If most of the top 10 Indian drug companies were less than Rs 500-crore (Rs 5-billion) turnover ones a decade earlier and were focused only on domestic business, now they are companies with annual businesses ranging from Rs 2,000-Rs 6,000 crore (Rs 20-60 billion) and with operations spanning 60-100 countries and employing 3,000-5,000 people.

No place like home, finds indian pharma

No place like home, finds indian pharma

Rediff.com   8 Feb 2010

An analysis of the growth rate of 15 leading drug companies for the third quarter of 2008-09 show excellent performances in domestic turf have been often marred by the poor show of their acquired assets.

Sahara set to buy out Siva from Aamby Valley

Sahara set to buy out Siva from Aamby Valley

Rediff.com   5 Feb 2010

The deal size could be in excess of Rs 2,000 crore, though this could not be verified. Sivasankaran had invested close to Rs 1,800 crore in 2007 to take a 41 per cent stake in Aamby Valley. The Sahara Group is the majority investor, with a 51 per cent stake.

Docs eye co-ownership of healthcare facilities

Docs eye co-ownership of healthcare facilities

Rediff.com   1 Feb 2010

In this emerging trend, doctors are joining hands with venture capitalists, drug firms and medical equipment vendors to set up advanced medical care facilities at low costs.

Reliance, L&T-led consortia eye B'lore Metro deal

Reliance, L&T-led consortia eye B'lore Metro deal

Rediff.com   1 Feb 2010

This metro line would be a 33.65-km rail link between Bangalore City Centre and Bangalore International Airport.

Siemens makes India R&D hub

Siemens makes India R&D hub

Rediff.com   1 Feb 2010

It has 150 research and development locations in over 30 countries around the world, employing over 32,300 people.

MNCs' high-end research has a new address: India

MNCs' high-end research has a new address: India

Rediff.com   1 Feb 2010

the early 1980s, multinationals set up R&D units in India to make use of the low costs and huge talent pool.

Docs, VCs come together for low-cost healthcare

Docs, VCs come together for low-cost healthcare

Rediff.com   28 Jan 2010

In this emerging trend, doctors are joining hands with venture capitalists, drug firms and medical equipment vendors to set up advanced medical care facilities at low costs.

US to curb delay in entry of generic drugs

US to curb delay in entry of generic drugs

Rediff.com   20 Jan 2010

Indian pharmaceutical companies, which are increasingly choosing to settle patent litigation with global drug majors in the US, would have to be more cautious now.

R-Infra to get Mumbai Metro-II on Jan 21

R-Infra to get Mumbai Metro-II on Jan 21

Rediff.com   20 Jan 2010

Anil Dhirubhai Ambani Group company Reliance Infrastructure (R-Infra) will soon be the official owner of the second phase of the Mumbai Metro project. The state government and the company will sign a concession agreement for the Rs 11,000-crore (Rs 110 billion) project on Thursday, according to sources.

Wockhardt-Abbot deal gets high court go-ahead

Wockhardt-Abbot deal gets high court go-ahead

Rediff.com   18 Jan 2010

The court's stand is expected to help Wockhardt conclude the deal within a month's time.

Indian generics dominate global ranking

Indian generics dominate global ranking

Rediff.com   12 Jan 2010

The BCG analysis shows Lupin gave an annualised average TSR of 29.9 per cent, ahead of the 18.4 per cent of Israel-based Teva Pharmaceutical, the world's largest generics maker. Teva is next on the list. Another Indian generic maker, Glenmark, occupies third position, with an 18 per cent TSR to its investors.

Water treatment, access becomes fast-growing biz

Water treatment, access becomes fast-growing biz

Rediff.com   11 Jan 2010

Orders are flowing for the water and wastewater treatment industry, as leading players in the domestic market such as VA Tech Wabag, Larsen and Toubro, Thermax and IVRCL Infra have bagged over Rs 2,500 crore (Rs 25 billion) worth of orders in the past two-to-three months.

Novartis gets patent for cancer drug

Novartis gets patent for cancer drug

Rediff.com   11 Jan 2010

Novartis markets Nilotinib globally as Tasigna, which is used as the second-line therapy for Gleevec-resistant patients in the case of chronic myelogenous leukemia.